Target to Patient 2024 – marketing pack

- **Event hashtag ‘join the conversation’:** #Target2Patient

- **Webpage:** [https://www.ebi.ac.uk/targettopatient/](https://www.ebi.ac.uk/targettopatient/)

- **Supported by:** Elrig, SMR

- **Sponsors:** EMBL-EBI, GSK, AstraZeneca, Ultima Genomics

- **Exhibitors:** Pelago, Ultima Genomics, Collaborative Drug Discovery, My Name’5 Doddie Foundation

- **Committee:** EMBL-EBI, GSK, Pfizer, AstraZeneca, NPL, Imperial College London

- **Relevant hashtags:** #AIML #digitalhealth #novel modalities #drugdiscovery #clinicaltrial #genomics #in vitro technologies #bioinformatics #drugtargets #clinicaltrialsdesign

- **Event description:** Target to Patient conference is returning to Hinxton Hall Conference Centre, Wellcome Genome Campus, Cambridge, UK OR online via our dedicated Target to Patient conference web portal. Advances in genomics for target choice, in vitro technologies, novel modalities, risk mitigation, data analysis, AI/ML and digital health are transforming our understanding of disease leading to an explosion of new opportunities in drug discovery. Join us to hear scientific
leaders explore how these advances are being used to identify new drug targets and create opportunities for improved pre-clinical work and clinical trials design.

- **Additional info:** Both audiences, face-to-face and virtual, will experience presentations from our esteemed panel of speakers, participate in live Q&A and panel discussion sessions, take advantage of networking opportunities, poster sessions, vendor exhibitions and on-demand materials.

This meeting will focus on ground-breaking advances in genomics for target choice, in vitro technologies, novel modalities, risk mitigation, data analysis, AI/ML, digital health, and how they could radically increase the discovery of disease relevant biological targets and the development of new drugs.

Abstracts for consideration for poster presentations can be submitted during registration.

- **Target audience:** Participants from industry, academia and government interested in challenging the existing approaches to target selection and translation are encouraged to attend and set the agenda for the next era of drug discovery.

- **Keynotes:**
  - Professor Sir Munir Pirmohamed, NHS Chair of Pharmacogenetics, University of Liverpool, UK
  - Dr. Melanie Lee CBE, Formerly CEO, LifeArc, CEO, Think 10

**Social media content:**

<table>
<thead>
<tr>
<th>Date</th>
<th>Channel</th>
<th>Topic</th>
<th>Content</th>
<th>Image</th>
</tr>
</thead>
<tbody>
<tr>
<td>Twitter</td>
<td>Registration announcement</td>
<td>Early bird registration is now open for #Target2Patient 2024!</td>
<td>X:</td>
<td></td>
</tr>
<tr>
<td>LinkedIn</td>
<td>Registration announcement</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>----------</td>
<td>---------------------------</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| **Registration is now open for #Target2Patient, 29 – 30 April 2024!**

- Register before 26 February to receive an early bird discount.

[Link](https://www.ebi.ac.uk/targettopatient/?utm_source=external&utm_medium=Linkedin&utm_campaign=registration+annoucement)

Don’t miss this opportunity to hear the latest from industry leaders on how advances in #genomics for target choice, #invitro technologies, novel modalities, #AIML, and #digitalhealth can radically increase the

---

Join us at [@HinxtonHall](https://twitter.com/HinxtonHall), or online to hear about the latest advances in **#genomics**, **#invitro technologies**, **#AIML** and **#digitalhealth** for drug development.

- **29-30 April 2024**

[Link](https://www.ebi.ac.uk/targettopatient/?utm_source=external&utm_medium=Twitter&utm_campaign=registration+annoucement)

(tag in picture: @ELRIG, @EMBL-EBI, @GSK, @AstraZeneca, @HinxtonHall @wellcomegenome)
| discovery of disease relevant biological targets and the development of new drugs. |
| Hinxton Hall Conference Centre, Cambridgeshire, UK, or online via our dedicated conference web portal |
| Supported by: ELRIG UK, Society for Medicines Research |
| Our sponsors: European Bioinformatics Institute | EMBL-EBI, GSK, AstraZeneca |
| (tag in picture: National Physical Laboratory (NPL, Imperial College London)) |